BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma
Juliet Richman, Juan Martin-Liberal, Stefan Diem & James Larkin
abstract |
INTRODUCTION AREAS COVERED Dual BRAF and MEK inhibition in advanced BRAF-mutated melanoma is superior to single inhibition in terms of efficacy without significant increase in toxicity. Therefore, BRAF plus MEK inhibition is expected to supersede single-agent BRAF inhibition in these patients in the near future. |
citation | Richman J, Martin-Liberal J, Diem S, Larkin J. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Expert Opin Pharmacother 2015; 16:1285-97. |
type | journal paper/review (English) |
date of publishing | 6-2015 |
journal title | Expert Opin Pharmacother (16/9) |
ISSN electronic | 1744-7666 |
pages | 1285-97 |
PubMed | 26001180 |
DOI | 10.1517/14656566.2015.1044971 |